Navigation Links
AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
Date:11/17/2009

NEW HAVEN, Conn., Nov. 17 /PRNewswire/ -- HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as one of the "... promising new strategies being developed for the measurement of ER and PgR in breast cancer tissue." Experts from the country's leading cancer treatment institutions responded in the report to growing concerns about hormone receptor testing in breast cancer by standard immunohistochemistry (IHC) methodology, particularly a high false-negative rate, and clarified how such testing can be improved. Hormone receptor testing, which includes estrogen receptor (ER) and progesterone receptor (PgR), is a standard part of the diagnostic characterization of an individual's breast cancer and drives treatment decision making.

"The NCCN Task Force Report demonstrates the growing confidence within oncology circles that AQUA analysis provides a new and promising approach to hormone receptor testing," said Rana K. Gupta, CEO of HistoRx. "We believe the upcoming ASCO-CAP guidelines will reinforce the Task Force's assessment that current methods of ER testing are flawed and will further underscore the need for a better solution. AQUA technology's sensitivity, reproducibility and quantification improve upon standard immunohistochemistry testing and can play an important role in improving the overall accuracy of hormone receptor testing."

An early example of personalized medicine, ER testing and PgR testing are typically performed by standard IHC. AQUA® technology brings standardization and reproducibility to IHC analysis and is the only platform capable of precisely measuring protein biomarker concentration with
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... 2013 Enrollment of patients with Type 2 ... clinical trial of product candidate NewMet ™, a ... Type 2 diabetes. Elcelyx expects to complete enrollment of ... Results of the trial,s primary endpoint of change in ... the read-out for long-term glucose lowering and weight benefits ...
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... , PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; ... Drug Administration (FDA) approved an additional intended use for its ... comprised of up to 96 individual donations. The test, called ... cobas s 201 system, is a qualitative, in-vitro test ...
... , EAST HANOVER, N.J., Dec. ... late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a ... company,s hematology portfolio in advancing the care of patients. ... Hematology (ASH) Annual Meeting and Exposition, highlight the company,s current ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25
(Date:5/20/2013)... Parker Waichman LLP, a national law ... by defective drugs, has filed a lawsuit on behalf ... of the diabetes drug medication Actos (pioglitazone) caused ... 30, 2013, in the U.S. District Court for the ... is one of thousands of cases pending in the ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
(Date:5/20/2013)... Mirena IUD lawsuit claims ... recently established in U.S. District Court, Southern District of ... court records, the litigation’s first Status Conference was held ... leadership positions were discussed. So far, at least ... of New York, all of which allege that the ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... and binge eating , MONDAY, May 10 (HealthDay News) ... the risk of impulse control disorders, such as problem ... In a new study that included 3,090 patients being ... the United States and Canada, the researchers found that ...
... ... Health Services, Inc. (CV10-2011), asserts that Gentiva, which employs some 30,000 health care workers, treats ... FLSA and refuses to pay these employees for all hours worked. , ... New York, NY (PRWEB) May 10, 2010 -- ...
... . Montreal, May 10, 2010 As fewer people ... among North American youth. A study published in the journal ... Montreal had used waterpipes (also known as shishas or hookahs) in ... due in part to perceptions that they are safer than cigarettes. ...
... Nurse staffing ... newly adopted U.S. Health Care Reform legislation. Current healthcare reform legislation indicates that more ... , ... (PRWEB) May 10, 2010 -- Nurse staffing agency, FlexRN, announces its plans to help agency ...
... treatment even when pulmonary disease looks stable, researchers ... of chronic obstructive pulmonary disease (COPD) leads to increased ... study finds. , British researchers looked at 25,857 COPD ... and 633 ischemic strokes (blockage of blood flow to ...
... from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown ... therapy to "rescue" treatment sensitivity to fulvestrant in estrogen ... on May 15, 2010 as the cover story of ... common second-line therapy for women whose cancer progresses following ...
Cached Medicine News:Health News:Parkinson's Drugs Tied to Compulsive Behaviors 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 3Health News:FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform 2Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2
... The MEL 80 is a top quality ... the correction of vision defects even safer, ... of this ultramodern work platform are oriented ... and the rapid recovery of vision. Key ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
... Escort Controller can be mounted at the ... table top. The design retains many ... controller, such as the pump drive motor ... pump, and infusion system. Retaining these ...
Medicine Products: